-
Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology
•
Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series A financing round led by Wedo Capital, with contributions from Qingdao Conson Financial Holdings. Proceeds will go towards phospholipid-coated microbubbles technology platform construction, phospholipid-coated microbubbles ultrasound contrast pipeline development, and industrialization. Company Background and TechnologyFounded…
-
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
•
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD 21.49 million) in a Series A financing round, led by Chengdu Wenjiang Emerging Industry Venture Capital Fund Partnership Limited, Tigermed Consulting, Yingke PE, Huaxin Asset Management, and Sichuan Mansaisi Pharma. Company Background and PipelineFounded in…
-
Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing
•
Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of millions” of renminbi in Series C1 and C2 financing rounds. Guotai Junan Innovation Investment led the former while Shanghai Science and Technology Innovation Center Equity Investment Fund led the latter. The funding rounds included contributions…
-
Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments
•
China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to RMB 100 million (USD 14.3 million) in a Series A+ financing round led by InnoStar Capital. Mingheng Industrial Investment and Zhongzhi Zhonghe Technology Consulting Center also took part in the funding, proceeds of which will…
-
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
•
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the National Reimbursement Drug List (NRDL) on-site negotiations process for this year, citing COVID-19 disruptions and ongoing workload related to preparing for the negotiations. When a new time slot is decided, the negotiating groups will be…
-
MaxHealth Biotechnology Completes Series B+ Financing Round
•
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong…
-
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
•
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Spain, and Estonia for its novel anti-microbial agent MRX-4 combined with contezolid (MRX-I) as a sequential treatment for diabetic foot infection. Drug Overview and DevelopmentBoth drugs are in-house developed new-generation oxazolidinone antibiotics.…
-
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
•
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to its proposed takeover by Sino Biopharmaceutical Ltd (HKG: 1177) subsidiary invoX Pharma. The proposed USD 161 million acquisition of F-Star by Sino Bio has attracted the attention of the US Committee on Foreign Investment to…
